News

ISRG's expanding robotic surgery ecosystem and innovation pipeline give it an edge over Abbott for investors seeking stronger long-term MedTech growth.

CNMD's FDA-expanded AirSeal indication adds da Vinci 5 hex cannula compatibility, supporting broader use across Intuitive Surgical's robotic systems.

Qualcomm, Intuitive Surgical and Stryker lead today's top analyst reports, spotlighting growth drivers, strategic initiatives and ongoing challenges.

According to the average brokerage recommendation (ABR), one should invest in Intuitive Surgical (ISRG). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Investors reacted to enterprise spending delays, healthcare competition, and weakening consumer demand.

QUALCOMM is expanding beyond smartphones with growth in automotive, edge AI and data centers, but competition and weak China demand remain key challenges.

Intuitive Surgical stock sinks as FDA announces marketing authorization for Johnson & Johnson’s Ottava platform. Here’s why the news is largely bearish for ISRG shares.

For Intuitive Surgical, fair value estimates have been reset from US$565.25 to US$501.73, pointing to a more measured view of potential upside versus earlier assumptions. Recent analyst commentary frames this shift as an expectations reset, with most firms keeping positive or neutral ratings while trimming price targets to account for slower procedure growth, Affordable Care Act related volume uncertainty, and tighter MedTech valuation multiples. Read on to see how to track these evolving...

Intuitive Surgical's growth rests on da Vinci 5, Ion, SP and digital tools as recurring revenue rises and procedure risks persist.

ISRG's growth is fueled by robotic surgery, Ion lung biopsy and AI tools, while tariffs, product mix and softer demand pressure margins.

ISRG's strong procedure growth, recurring revenue and cash position support its case, but tariffs, mix shifts and placement risks cloud the outlook.

Intuitive Surgical's valuation has eased as U.S. procedure growth slows, but margin gains, AI software expansion and global growth could support its premium.

By Puyaan Singh July 22 (Reuters) - Johnson & Johnson said on Wednesday the U.S.

At first glance, its numbers were impressive.

At $353, Intuitive Surgical (ISRG) is being priced to deliver 14.1% revenue growth annually for the next 4 years simply to defend today's 42.1x multiple. That sits below the 21% the business is currently growing at, which is the unusual part. The multiple has already priced in a slowdown that has not yet appeared.

NZS Capital, LLC, an investment management company, released its “NZS Growth Equity Strategy” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. Equity markets delivered a strong performance in the second quarter of 2026, driven by demand for AI infrastructure, geopolitical stabilization, and positive earnings reports. The portfolio achieved a gross […]

Shares of Intuitive Surgical are down nearly 40% this year.

NZS shifts capital toward AI infrastructure and healthcare leaders

You can be forgiven for doing a double-take on Intuitive Surgical (ISRG) on Friday. The company posted second-quarter revenue of $2.89 billion, up 19% from a year ago and comfortably ahead of Wall Street estimates. Yet the stock ended the day down 14.1%, closing at a new 52-week low.

The surgical robotics giant beat estimates, but a moderation in its core US market has investors questioning the whole story.

Intuitive Surgical (ISRG) possesses solid growth attributes, which could help it handily outperform the market.

Intuitive Surgical (ISRG) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Intuitive Surgical (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The Morning Bull - US Market Morning Update Monday, Jul, 20 2026 US stock futures are pointing lower this morning, with E mini S&P 500 contracts down around 1%, as investors weigh falling bond yields against a cooling housing backdrop. The US 10 year Treasury yield has slipped to about 4.5% after softer inflation readings. In plain terms, this means borrowing costs in financial markets are easing a little even as the debate over the Federal Reserve's next move continues. At the same time,...

The robot-assisted surgery pioneer's growth could be decelerating.

The robotics and automation fund is down, and its own record suggests a rebound is more common than not, but the ride has rarely been smooth.

Intuitive Surgical shares fell about 10% after Q2 2026 revenue rose 19% but guidance for da Vinci procedure growth wasn't raised, pushing ISRG below its 200-week moving average.

A number of stocks fell in the afternoon session after a key industry player warned that changes to some insurance plans could slow U.S. procedure growth, sparking fears of a sector-wide slowdown. The concern was raised by Intuitive Surgical, which noted that shifting insurance coverage could dampen the number of medical procedures performed in the United States. This news has investors worried about near-term demand, not just for one company, but for the entire industry reliant on a steady volu

(Updates with index/price moves, macroeconomic data and company/geopolitical news from the first par

(Updates with market moves at the end of the day and weekly index changes.) US equities declined